An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy studyon May 8, 2024 at 11:18 am
Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to ...
- Clinical trials show promise in oral immunotherapy to tackle food allergieson May 8, 2024 at 9:07 am
Two years into its three-year run, The Natasha Foundation has seen positive results from its clinical trial aiming to help desensitise children with food allergies using a technique known as oral ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapyon May 7, 2024 at 9:46 pm
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer ...
- FDA approves new immunotherapy treatment for melanomaon May 6, 2024 at 5:45 pm
Melanoma is considered the deadliest of all skin cancers. Now the FDA has approved an immunotherapy treatment that could help extend lives. The single-dose immunotherapy is currently approved for ...
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
"These findings uncover new tactics that are employed by cancer to escape from immune cell attack and explain why some cancer immunotherapy strategies do not work well in the clinic," said Lieping ...
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Ketone supplement may boost immunotherapy against prostate canceron May 2, 2024 at 9:00 am
Researchers have found that adding a pre-ketone supplement to immunotherapy boosted its effectiveness against prostate cancer in mouse models.
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Successon April 30, 2024 at 8:27 am
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
via Bing News